| Fondaparinux as alternative anticoagulant to warfarin or low-molecular-weightheparin for recurrent venous thrombosis. | Ann Pharmacother | 2014 Mar | 24473488 |
| New oral anticoagulants in practice: pharmacological and practicalconsiderations. | Am J Cardiovasc Drugs | 2014 Jun | 24452600 |
| Beyond warfarin: a patient-centered approach to selecting novel oralanticoagulants for stroke prevention in atrial fibrillation. | J Hosp Med | 2014 Jun | 24715600 |
| Acquired absolute vitamin K deficiency in a patient undergoing warfarin therapy. | Am J Emerg Med | 2014 Jun | 24439543 |
| European cardiac nurses' current practice and knowledge on anticoagulationtherapy. | Eur J Cardiovasc Nurs | 2014 Jun | 23711557 |
| Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverseevent reporting system during the first year of approval. | Pharmacotherapy | 2014 Jun | 24644100 |
| New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? | Clin Pharmacol Ther | 2014 Jul | 24942397 |
| Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1genotype-dependent influence of dietary vitamin K intake. | J Thromb Thrombolysis | 2014 Jul | 23928870 |
| Patients satisfaction with warfarin and willingness to switch to dabigatran: apatient survey. | J Thromb Thrombolysis | 2014 Jul | 23918529 |
| [New treatments for stroke and thromboembolism prevention in atrialfibrillation]. | Harefuah | 2014 Jan | 24605405 |